Abstract 2089P
Background
Febrile neutropenia (FN) resulting from myelosuppressive chemotherapy drugs, have the potential to necessitate dose reduction or treatment delays, thus compromising the overall efficacy of treatment. This study aims to analyze the incidence of FN and related adverse drug reactions in cancer patients who receive prophylaxis with PEG-rhG-CSF (a long-acting granulocyte colony-stimulating factor).
Methods
This real-world study was conducted as a multicenter, retrospective, observational research involving adult cancer patients who received chemotherapy with PEG-rhG-CSF prophylactic. The study focused on several variables, including baseline characteristics and incidence of FN. Descriptive analysis was performed by using IBM SPSS Statistics 27.
Results
24,199 patients were enrolled from 575 hospitals across China between June 2022 and January 2023. The chemotherapy cycle records encompassed 1to 20 cycle. Among the enrolled patients, breast cancer was the most prevalent tumor type, accounting for 33.6% (N=8,131) of the cases. FN incidence across all cycles was 0.054% and it was 0.055% and 0.053% among patients receiving PEG-rhG-CSF as primary and secondary prophylaxis. These rates were significantly lower than the previously reported data of 13% to 21% from a retrospective cohort study involving patients with or without prophylaxis. Overall, FN occurred across the first to eighth cycles with the highest incidence observed in cycle 1 (52.50%). 1,659 records (2.25%) reported adverse events related to PEG-rhG-CSF. The most commonly observed adverse effect was musculoskeletal pain, accounting for 1.53% of the cases, followed by fatigue(0.60%) and allergic reactions(0.07%). Furthermore, 90.78% of adverse reactions were categorized as primary or secondary adverse reactions.
Conclusions
Under PEG-rhG-CSF prophylaxis, cancer patients exhibited a low incidence of FN which primarily occurred in the initial cycle of chemotherapy. Importantly, the administration of PEG-rhG-CSF was well tolerated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06